STING pathway contributes to the prognosis of hepatocellular carcinoma and identification of prognostic gene signatures correlated to tumor microenvironment

Pu, Zhangya; Liu, Jinghua; Liu, Zelong; Peng, Fang; Zhu, Yuanyuan; Wang, Xiaofang; He, Jiayan; Yi, Panpan; Hu, Xingwang; Fan, Xuegong; Chen, Jiang

doi:10.1186/s12935-022-02734-4

Table 3 The correlation of VAV1, RHOA, and ZC3HAV1 transcriptional expression and immunotherapy response based on various cancer cohorts from TIDE database

From: STING pathway contributes to the prognosis of hepatocellular carcinoma and identification of prognostic gene signatures correlated to tumor microenvironment

Cohort name	Cancer type	Cases	Survival	VAV1			RHOA			ZC3HAV1
Cohort name	Cancer type	Cases	Survival	CTL Cor	Risk	Risk.adj	CTL Cor	Risk	Risk.adj	CTL Cor	Risk	Risk.adj
Braun2020_PD1	Kidney	295	OS	0.074	− 2.675	− 2.358	− 0.056	− 2.039	− 1.904	NA	NA	NA
Gide2019_PD1	Melanoma	41	OS	0.839	− 1.512	1.3	− 0.024	1.642	1.3	0.533	− 1.545	0.302
Gide2019_PD1 + CTLA4	Melanoma	32	OS	0.858	− 1.297	− 1.251	0.085	− 0.833	− 0.919	0.469	− 1.636	− 1.268
Hugo2016_PD1	Melanoma	25	OS	0.835	0.707	− 0.145	− 0.083	− 0.893	− 0.884	0.191	0.692	0.688
Lauss2017_ACT	Melanoma	25	OS	0.872	− 0.439	0.012	− 0.115	− 0.295	− 0.299	0.423	0.711	1.122
Liu2019_PD1	Melanoma	47	OS	0.69	− 2.263	− 1.643	0.114	− 1.411	− 1.184	0.361	− 0.518	0.036
Liu2019_PD1	Melanoma	74	OS	0.59	− 2.201	− 2.874	0.114	− 2.399	− 2.326	0.394	− 1.451	− 1.171
Mariathasan2018_PDL1	Bladder	348	OS	0.708	− 0.249	1.82	0.187	− 0.194	0.198	0.497	0.117	1.306
Miao2018_ICB	Kidney	33	OS	0.599	− 0.928	− 1.108	0.262	0.408	− 0.24	0.298	− 0.89	− 1.023
Nathanson2017_CTLA4	Melanoma	9	OS	0.803	1.784	2.067	0.017	0.602	0.723	0.392	− 0.33	1.435
Nathanson2017_CTLA4	Melanoma	15	OS	0.886	− 2.018	− 0.834	0.291	− 0.134	− 0.534	− 0.195	− 0.067	0.165
Riaz2017_PD1	Melanoma	25	OS	0.833	0.05	1.014	0.298	0.532	0.708	0.453	0.968	0.894
Riaz2017_PD1	Melanoma	26	OS	0.805	− 1.656	− 1.71	0.192	− 1.52	− 1.043	0.293	− 0.712	− 0.637
VanAllen2015_CTLA4	Melanoma	42	OS	0.797	− 2.399	− 0.823	0.16	− 1.757	− 1.446	0.564	− 2.052	− 0.904
Zhao2019_PD1	Glioblastoma	15	OS	0.701	0.546	0.592	− 0.31	− 0.634	− 0.668	0.083	0.904	1.731
Zhao2019_PD1	Glioblastoma	9	OS	0.383	− 1.467	− 1.319	0.409	− 1.749	− 1.511	0.501	− 0.422	− 0.55
Braun2020_PD1	Kidney	295	PFS	0.074	− 0.181	− 0.114	− 0.056	− 0.896	− 0.792	NA	NA	NA
Gide2019_PD1	Melanoma	41	PFS	0.839	− 2.269	1.434	− 0.024	1.9	1.99	0.533	− 1.521	0.883
Gide2019_PD1 + CTLA4	Melanoma	32	PFS	0.858	− 0.774	1.201	0.085	− 0.116	− 0.084	0.469	− 0.334	0.485
Lauss2017_ACT	Melanoma	25	PFS	0.872	− 0.504	0.396	− 0.115	0.842	0.977	0.423	1.353	2.345
Liu2019_PD1	Melanoma	74	PFS	0.59	− 0.891	− 0.512	0.304	0.454	0.525	0.361	0.086	1.035
Liu2019_PD1	Melanoma	47	PFS	0.69	− 2.684	− 1.365	0.304	− 0.245	0.019	0.394	0.742	0.92
Miao2018_ICB	Kidney	33	PFS	0.599	− 1.757	− 2.72	0.262	− 0.472	− 0.474	0.298	− 1.567	− 1.943
Riaz2017_PD1	Melanoma	25	PFS	0.833	0.69	0.821	0.298	0.092	− 0.059	0.453	0.542	0.892
Riaz2017_PD1	Melanoma	26	PFS	0.805	− 2.412	− 1.981	0.192	− 1.363	− 1.222	0.293	− 1.571	− 1.261
VanAllen2015_CTLA4	Melanoma	42	PFS	0.797	− 1.7	− 0.487	0.16	− 1.358	− 0.979	0.564	− 1.041	− 0.012
Zhao2019_PD1	Glioblastoma	15	PFS	0.701	0.028	0.169	− 0.31	− 1.021	− 1.06	0.083	0.507	1.685
Zhao2019_PD1	Glioblastoma	9	PFS	0.383	− 1.939	− 1.63	0.409	− 1.722	− 1.679	0.501	− 1.089	− 1.105

TIDE: tumor immune dysfunction and exclusion. Cor. Pearson’s correlation coefficient. Risk.adj: Risk adjustment. OS: overall survival. PFS: progression-free survival. CTL: cytotoxic T lymphocyte. NA: not applicable

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Cell International

Contact us